DOCSLIB.ORG

Metabolic Signatures in Coronary Artery Disease: Results from the Bioheart-CT Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Metabolic Signatures in Coronary Artery Disease: Results from the Bioheart-CT Study cells Article Metabolic Signatures in Coronary Artery Disease: Results from the BioHEART-CT Study Stephen T. Vernon 1,2,3, Owen Tang 1,3,4, Taiyun Kim 4,5,6 , Adam S. Chan 4,5, Katharine A. Kott 1,2,3 , John Park 1, Thomas Hansen 1,3, Yen C. Koay 4,7,8, Stuart M. Grieve 9,10, John F. O’Sullivan 4,7,8,†, Jean Y. Yang 4,5,† and Gemma A. Figtree 1,2,3,4,*,† 1 Cardiothoracic and Vascular Health, Kolling Institute, Northern Sydney Local Health District, Sydney, NSW 2065, Australia; [email protected] (S.T.V.); [email protected] (O.T.); [email protected] (K.A.K.); [email protected] (J.P.); [email protected] (T.H.) 2 Department of Cardiology, Royal North Shore Hospital, Sydney, NSW 2065, Australia 3 Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia 4 Charles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia; [email protected] (T.K.); [email protected] (A.S.C.); [email protected] (Y.C.K.); [email protected] (J.F.O.); [email protected] (J.Y.Y.) 5 School of Mathematics and Statistics, University of Sydney, Sydney, NSW 2006, Australia 6 Computational Systems Biology Group, Children’s Medical Research Institute, Westmead, NSW 2145, Australia 7 Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia 8 Heart Research Institute, The University of Sydney, Sydney, NSW 2042, Australia 9 Imaging and Phenotyping Laboratory, Charles Perkins Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia; [email protected] 10 Citation: Vernon, S.T.; Tang, O.; Kim, Department of Radiology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia * Correspondence: gemma.fi[email protected] T.; Chan, A.S.; Kott, K.A.; Park, J.; † Contributed equally. Hansen, T.; Koay, Y.C.; Grieve, S.M.; O’Sullivan, J.F.; et al. Metabolic Abstract: Signatures in Coronary Artery Despite effective prevention programs targeting cardiovascular risk factors, coronary Disease: Results from the artery disease (CAD) remains the leading cause of death. Novel biomarkers are needed for im- BioHEART-CT Study. Cells 2021, 10, proved risk stratification and primary prevention. To assess for independent associations between 980. https://doi.org/10.3390/ plasma metabolites and specific CAD plaque phenotypes we performed liquid chromatography cells10050980 mass-spectrometry on plasma from 1002 patients in the BioHEART-CT study. Four metabolites were examined as candidate biomarkers. Dimethylguanidino valerate (DMGV) was associated with Academic Editor: János G. Filep presence and amount of CAD (OR) 1.41 (95% Confidence Interval [CI] 1.12–1.79, p = 0.004), calcified plaque, and obstructive CAD (p < 0.05 for both). The association with amount of plaque remained Received: 14 March 2021 after adjustment for traditional risk factors, ß-coefficient 0.17 (95% CI 0.02–0.32, p = 0.026). Glutamate Accepted: 20 April 2021 was associated with the presence of non-calcified plaque, OR 1.48 (95% CI 1.09–2.01, p = 0.011). Pheny- Published: 22 April 2021 lalanine was associated with amount of CAD, ß-coefficient 0.33 (95% CI 0.04–0.62, p = 0.025), amount of calcified plaque, (ß-coefficient 0.88, 95% CI 0.23–1.53, p = 0.008), and obstructive CAD, OR 1.84 Publisher’s Note: MDPI stays neutral (95% CI 1.01–3.31, p = 0.046). Trimethylamine N-oxide was negatively associated non-calcified plaque with regard to jurisdictional claims in p published maps and institutional affil- OR 0.72 (95% CI 0.53–0.97, = 0.029) and the association remained when adjusted for traditional risk iations. factors. In targeted metabolomic analyses including 53 known metabolites and controlling for a 5% false discovery rate, DMGV was strongly associated with the presence of calcified plaque, OR 1.59 (95% CI 1.26–2.01, p = 0.006), obstructive CAD, OR 2.33 (95% CI 1.59–3.43, p = 0.0009), and amount of CAD, ß-coefficient 0.3 (95% CI 0.14–0.45, p = 0.014). In multivariate analyses the lipid and nucleotide Copyright: © 2021 by the authors. metabolic pathways were both associated with the presence of CAD, after adjustment for traditional Licensee MDPI, Basel, Switzerland. risk factors. We report novel associations between CAD plaque phenotypes and four metabolites This article is an open access article previously associated with CAD. We also identified two metabolic pathways strongly associated distributed under the terms and with CAD, independent of traditional risk factors. These pathways warrant further investigation at conditions of the Creative Commons both a biomarker and mechanistic level. Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Cells 2021, 10, 980. https://doi.org/10.3390/cells10050980 https://www.mdpi.com/journal/cells Cells 2021, 10, 980 2 of 16 Keywords: coronary artery disease; metabolites; risk factors; atherosclerosis; metabolomics 1. Introduction Large longitudinal epidemiological studies have identified a number of modifiable risk factors and disease processes associated with cardiovascular disease (CVD), including hypertension, hyperlipidaemia, cigarette smoking, and diabetes mellitus [1]. Public health and primary prevention programs targeting these modifiable risk factors have substantially reduced the burden of disease at the community level [2]. Despite this, coronary artery disease (CAD) remains the leading cause of death globally and at an individual level it is not uncommon for people to suffer life threating cardiovascular events such as ST elevation myocardial infarction in the absence of these well described risk factors [3–7]. Clinically utilised biomarkers, including standard lipid profiles, blood glucose levels, and HbA1c, reflect established traditional risk factors or CAD, however we lack biomarkers that reflect the residual risk not captured by traditional risk factors. Computed tomography coronary angiography (CTCA) can non-invasively assess and characterise coronary artery plaque, as well as clearly identify normal coronary arteries (the absence of plaque). This provides a powerful research opportunity for CAD biomarker discovery studies, overcoming a challenge faced by many prior studies that relied on cardiovascular events to define CAD, where many of the healthy control participants actually have substantial subclinical atherosclerosis [8–10] BioHEART-CT, a multicentre, prospective cohort study of patients with suspected CAD, utilises detailed demographic, clinical, and CTCA data to accurately quantify the disease burden in its participants, and stored blood samples for molecular phenotyping. It has been designed to identify novel biomarkers associated with CAD in order to improved risk stratification and to identify new mechanistic pathways that could be targeted to reduce the burden of CAD [11]. Metabolites are influenced by environmental factors, genetic factors, and interactions between the two [12,13]. Metabolomics, the systematic identification and quantification of small molecules (up to 1.5 kDa) in biological fluids, thus reflects the metabolic state of the biological system at a point in time [14]. The metabolome can be assessed at a cellular, tissue, organ, or whole-organismal level. A recent systematic review of metabolomics studies attempting to identify metabolic signatures of incident cardiovascular disease identified 5 metabolites acylcarnitine, dicarboxylacylcarnitine, trimethylamine N-oxide (TMAO), phenylalanine, and glutamate [15]. Another recent study identified an indepen- dent association between dimethylguanidino valerate (DMGV) and incident CAD [16]. We hypothesised that there are circulating metabolites and shifts in particular metabolic pathways associated with the presence of CAD, and specific CAD phenotypes, including calcified plaque and non-calcified “soft” plaque. We utilised a large, well phenotyped cohort of stable patients with suspected CAD undergoing CTCA, and considered the role of traditional CAD risk factors. We proceeded to test these hypotheses in the BioHEART CT study, utilising liquid chromatography mass spectrometry. 2. Methods 2.1. BioHEART-CT Study BioHEART-CT is a multicentre, longitudinal, prospective cohort study of patients un- dergoing a CTCA for investigation of suspected CAD. BioHEART is a registered Australian and New Zealand Clinical Trial (ACTRN12618001322224). The study protocol and design has been approved by the Northern Sydney Local Health District Human Research Ethics Committee (HREC/17/HAWKE/343) and described in detail previously [11]. Informed written consent was obtained. Patient level information was collected using a structured data collection form at the time of recruitment and entered into a secure, encrypted database. Baseline data collected includes demographics, anthropometric measures, past medical diagnoses (cardiovascular diagnoses and risk factors), current medication use, and social Cells 2021, 10, 980 3 of 16 history. Standard Modifiable cardiovascular Risk Factors (SMuRFs) were recorded based on the self-reported history or use of pharmacotherapy for any of hypertension, hyperc- holesterolaemia, diabetes mellitus, or a significant smoking history. Current smoking was defined as having regularly smoked within the past 12 months, and significant smoking history was considered to be 10 packet years or greater. A significant family history of premature ischaemic heart disease in a first degree relative under the age of 60 years was recorded. Blood samples were taken at the time of recruitment
Load more

Recommended publications
  • 2007 Annual Report Annual Institute Eye Lions Review Molecular
    Lions Eye Institute ABN 48 106 521 439 2 Verdun Street, Nedlands WA 6009 General Administration & Research Enquiries 9381 0777 Administration & Research Facsimile 9381 0700 07 International +61 8 9381 0777 Clinical Facilities Elsie Gadd Eye Clinic Appointments 9381 0888 Day Surgery Facility 9381 0880 Laser Vision Centre 9381 0758 Clinical Facilities Facsimile 9382 1171 Annual REPORT 20 WWW.LEI.ORG.AU RAZOREYE LEI5693 02/08 Lions Eye Institute 2007 Annual Report Annual Report 2007 Corporate Directory Mission Lions Eye Institute Prof. Ian Constable AO Assoc. Prof. Geoffrey Crawford Administration & Finance Our mission is to achieve excellence Managing Director Director of Surgical Services [email protected] [email protected] Chee-Peng Yao in scientific research and clinical practice 9381 0871 Chief Financial Officer Esther McCloskey [email protected] to prevent blindness. Executive Assistant to Prof. Constable Assoc. Prof. Graham Barrett 9381 0703 [email protected] [email protected] 9381 0882 9381 0872 David Eiszele Dr Jean-Louis deSousa Information Technology Chairman [email protected] & Communications 9381 0777 9381 0747 Yaasin Lutta Dr Adam Gajdatsy Head of Information Technology [email protected] & Communications Research 9381 0763 [email protected] 9381 0786 Prof. P. Elizabeth Rakoczy Dr Antonio Giubilato Director of Research; [email protected] Director, Molecular Ophthalmology 9381 0819 [email protected] Lions Eye Bank 9381 0726 Dr Tim Isaacs [email protected] Stephanie Durham Coordinator Assoc. Prof. Mariapia Degli-Esposti 9381 0862 Co-Director, Centre for Experimental [email protected] Immunology; Assoc.
    [Show full text]
  • Finding Cures for Cardiovascular Disease Through World-Class Medical Research 02 VICTOR CHANG CARDIAC RESEARCH INSTITUTE IMPACT REPORT 2019 03
    IMPACT REPORT 2019 Finding cures for cardiovascular disease through world-class medical research 02 VICTOR CHANG CARDIAC RESEARCH INSTITUTE IMPACT REPORT 2019 03 For years the Victor Chang Cardiac Research Institute has Contents been Australia’s home of heart research. Since , the Institute has made an unshakeable contribution to the fight against About Us 4 Heart Disease Statistics 6 cardiovascular disease, and that PATIENT STORY SCAD Survivor 8 makes us overwhelmingly proud. Chairman’s Report 10 Executive Director’s Report 14 In ­­ we farewell our PATIENT STORY Cardiac Arrest Survivor 16 Organisational Structure 17 pioneering Executive Director, Board of Directors 18 Professor Bob Graham. 25 years of discovery 20 PROFILE Professor Bob Graham 24 Nevertheless, we are confident PROFILE Professor Diane Fatkin 34 that in Professor Jason Kovacic PROFILE Professor Livia Hool 38 Research Divisions Overview 42 we have a champion who will not Victor Chang Cardiac Research Institute Innovation Centre 44 only continue this legacy but take Sohn Hearts & Minds the Institute to the next level, as Investment Leaders Conference 46 Heart Health Checks 48 the new leader of the organisation. Statement of Income and Expenditure 49 Achievements and Awards 50 Fundraising Events 52 Supporters and Acknowledgments 54 This special 25th Anniversary edition is dedicated Support Life-Saving Heart Research 57 to you, our loyal supporters. After a quarter of a century, thanks to you, we’re only just getting started. Here’s to another 25 illustrious years! 04 VICTOR CHANG CARDIAC RESEARCH INSTITUTE IMPACT REPORT 2019 05 About Us Our Mission Our Statistics Australia’s home The relief of pain and suffering and the promotion of wellbeing, of heart research through an understanding of the fundamental The Victor Chang Cardiac Research mechanisms of researchers and staff cardiovascular biology in Institute is dedicated to finding cures health and disease.
    [Show full text]
  • Today's Research Tomorrow's Cure
    2018 Heart Research Institute Annual Review Accelerating Research Tomorrow’s cure Tomorrow’s Today’s research Today’s 2018 Heart Research Institute Annual Review Hello Future Accelerating 2018 Heart Research Institute Annual Review Research ACCELERATING Discoveries into therapies Knowledge into prevention Breakthroughs into cures Students into leaders Collaborations into partnerships 4 2018 Heart Research Institute Annual Review Inspiring Leaders 2018 Heart Research Institute Annual Review CONTENTS 06 HRI in 2018 08 Chairman’s Report 2018 10 Director of Cardiovascular Research Report 12 2018 Research and Media Highlights 16 Applied Materials Group 18 Atherosclerosis and Vascular Remodelling Group 20 Cardiac Imaging Group 22 Cardiometabolic Disease Group 24 Cardiovascular Medical Devices Group 26 Cell Therapeutics Group 28 Clinical Research Group 30 Haematology Research Group 32 Heart Rhythm and Stroke Prevention Group 34 High Blood Pressure Group 36 Thrombosis Group 38 Vascular Complications Group 40 Vascular Immunology Group 42 Inflammation and Fibrosis Research 44 PhD Students 45 Select Prizes and Awards 46 Select Conferences and Presentations 50 Select Publications 56 Board of Governors 59 International Board of Governors 60 Members of the Institute 62 Fundraising Report 66 Operations Report 6 2018 Heart Research Institute Annual Review The mission of the Heart Research Institute (HRI) is to prevent death and suffering from cardiovascular disease through an understanding of the biological processes that cause atherosclerosis and thrombosis, the major underlying causes of most heart attacks and strokes. 20 18 SHORT TERM LONG TERM The major short-term focus of our research There are four long-term objectives is to understand the development and for our research: progression of atherothrombotic conditions • To investigate mechanisms in which the arteries are narrowed and contributing to the pathogenesis restricted due to a build-up of fatty of cardiovascular disease.
    [Show full text]
  • Annual Report 2005, Baker Heart Research Institute
    Baker Heart Research Institute | Annual Report 2005 Annual Report 2005 Contents 2 The Baker story 4 Organisational Structure 6 Director’s Report 8 President’s Report 9 A word from our patron 10 The Board 12 Baker History 14 Summary of Baker relationships 15 Research & Divisions 16 Baker Clinical 17 ABMU 18 Experimental Cardiology and Heart Failure 19 Wynn Department of Cardiology 20 Cellular Biochemistry 21 Experimental Cardiology 22 Cardiac Hypertrophy 23 Cardiac Surgery 24 Applied Cardiovascular Research 25 Molecular Endocrinology 26 Molecular Pharmacology 27 Atherothrombosis and Vascular 28 Thrombosis & Myocardial Infarction 29 Cell Biology 30 Clinical Physiology 31 Vascular Pharmacology 32 Cell Biology & Diabetes 33 Lipoproteins & Atherosclerosis 34 Human & Vascular Biology 35 JDRF Diabetes and Metabolism 36 Oxidative Stress 37 Human Epigenetics 38 Biochemistry of Diabetic Complications 39 Kidney Disease in Diabetic Complications 40 Advanced Glycation in Diabetic Complications 41 Genomics of Diabetic Complications 42 Proliferation & Fibrosis in Diabetic Complications 43 Atherosclerosis in Diabetic Complications 44 Cardiovascular Neuroscience 45 Neuropharmacology 46 Translational Proteomics Ramaciotti Centre 47 Human Neurotransmitters 48 Commercialisation 60 Core Facilities 62 Staff & Students 66 Monthly Baker Science Awards 68 Development 67 Donors 70 Financial Report 73 Publications 76 Location & Contact details now in its 80th year, the Baker A comprehensive research Heart Research Institute is program with a strategic focus: The Baker story… Australia’s most distinguished Research at the Baker is broadly cardiovascular research centre divided into four divisions: and one of the world’s leading Experimental Cardiology and Heart organisations investigating Failure; Atherothrombosis and the causes and complications, Vascular; Diabetes and Metabolism treatment and prevention of heart, and Cardiovascular Neuroscience.
    [Show full text]
  • Snow Fellowship 2021 Application Round - Eligible Host Organisations
    Snow Fellowship 2021 Application Round - Eligible Host Organisations Entity name Asbestos Diseases Research Institute Australian Catholic University Limited Australian Centre for Heart Health Australian Institute of Aboriginal and Torres Strait Islander Studies Australian National University Baker Heart and Diabetes Institute Bionics Institute Black Dog Institute Bond University Limited Brien Holden Vision Institute Burnet Institute Centenary Institute of Cancer Medicine and Cell Biology Central Australian Aboriginal Congress Aboriginal Corporation Central Queensland University Centre for Eye Research Australia Limited Charles Darwin University Charles Sturt University Children's Cancer Institute Children's Medical Research Institute Chris O'Brien Lighthouse Curtin University Deakin University Doherty Institute Ear Science Institute Australia Incorporated Edith Cowan University Federation University Australia Flinders University Florey Institute of Neuroscience and Mental Health Garvan Institute of Medical Research George Institute for Global Health Griffith University Hanson Institute Harry Perkins Institute of Medical Research Heart Research Institute Hudson Institute of Medical Research Hunter Medical Research Institute Ingham Institute Institute for Breathing and Sleep James Cook University Kolling Institute of Medical Research La Trobe University Lions Eye Institute Macquarie University Snow Fellowship 2021 Application Round - Eligible Host Organisations Mater Research Limited Melanoma Institute Australia Menzies School of Health
    [Show full text]
  • Snow Fellowships 2020 Application Round - Eligible Host Organisations
    Snow Fellowships 2020 Application Round - Eligible Host Organisations Entity name Asbestos Diseases Research Institute Australian Catholic University Limited Australian Centre for Heart Health Australian Institute of Aboriginal and Torres Strait Islander Studies Australian National University Baker Heart and Diabetes Institute Bionics Institute Black Dog Institute Bond University Limited Brien Holden Vision Institute Burnet Institute Centenary Institute of Cancer Medicine and Cell Biology Central Australian Aboriginal Congress Aboriginal Corporation Central Queensland University Centre for Eye Research Australia Limited Charles Darwin University Charles Sturt University Children's Cancer Institute Children's Medical Research Institute Chris O'Brien Lighthouse Curtin University Deakin University Doherty Institute Ear Science Institute Australia Incorporated Edith Cowan University Federation University Australia Flinders University Florey Institute of Neuroscience and Mental Health Garvan Institute of Medical Research George Institute for Global Health Griffith University Hanson Institute Harry Perkins Institute of Medical Research Heart Research Institute Hudson Institute of Medical Research Hunter Medical Research Institute Ingham Institute Institute for Breathing and Sleep James Cook University Kolling Institute of Medical Research La Trobe University Lions Eye Institute Macquarie University Mater Research Limited Melanoma Institute Australia Menzies School of Health Research Monash University Murdoch Children’s Research Institute Murdoch
    [Show full text]
  • Annual Scientific Meeting of the Australian Atherosclerosis Society October 21 – 23, 2015, Fremantle, Western Australia Faculty Member Biographies
    Annual Scientific Meeting of the Australian Atherosclerosis Society October 21 – 23, 2015, Fremantle, Western Australia Faculty Member Biographies International Guest Speakers: Prof. Bart Staels, Pasteur Institute, Lille, France Prof. Bart Staels’ research focuses on molecular pharmacology of cardiovascular and metabolic diseases, including dyslipidemia and type 2 diabetes. He particularly studies the role of nuclear receptors (such as the PPARs, FXR, Rev-erba and RORa) in the control of inflammation and lipid and glucose homeostasis as well as the transcriptional mechanisms involved. Pr. Staels was among the first to identify a crucial role for the nuclear receptor PPARa in the control of lipid and glucose metabolism as well as cardiovascular function in humans. Dr Jean-Sébastien Silvestre From 1999 to 2007, he has been assistant professor at Paris-Diderot University and an honorary member of Institute Universitaire de France. Since 2008, he is research director at Institute Nationale de la Santé et de la Recherche Médicale (Inserm) and head of team 6 ‘regenerative therapies for cardiac and vascular diseases’ at the Paris Cardiovascular Research Center-Inserm UMRS 970 (Paris, France). His central interest lies in cardiovascular physiology and the role of vascular growth and remodelling in ischemic diseases. He has co-authored more than 100 published articles deciphering the molecular and cellular mechanisms involved in post-ischemic revascularization and tissue regeneration. Dr Bhama Ramkhelawon New York University Langone Medical Center Postdoctoral Fellow Bhama’s continuous eagerness to learn biological sciences brought her from Mauritius to France, where she obtained her PhD in cardiovascular diseases. She then moved to New York to gain expertise in the field of cardio-metabolic pathologies.
    [Show full text]
  • Menzies Research Institute Annual Report 2007 About Us
    Menzies Research Institute Annual Report 2007 About us At the Menzies Research Institute In 2000, the Tasmanian Government Our Research our aspiration is to contribute named Menzies a “Tasmanian Menzies’ researchers are currently significantly to improving human Icon” in recognition of our scientific working on over 100 projects that health and wellbeing. achievements, status and place in focus on preventing or curing a range the Tasmanian community. Menzies is renowned locally, nationally of diseases, including heart disease, and internationally for its research We underwent significant governance cancer, dementia, multiple sclerosis, excellence that utilises the competitive and structural changes in 2004, diabetes, cystic fibrosis, arthritis, advantages Tasmania has to offer. including a name change to the osteoporosis and mental health. Menzies Research Institute and the We are finding answers to local The research program at Menzies appointment of an independent Board. health problems that have global is organised around themes of significance. A significant ongoing growth research excellence: strategy was implemented in • Biostatistics; Tasmania is an ideal environment 2006 which saw Menzies undergo with many competitive advantages • Cancer; a dynamic transformation. We for medical research to thrive, • Cardiovascular Disease; became Tasmania’s premier medical including our small island research facility. Menzies’ research • Diabetes and Metabolism; geography, stable population, programs were expanded to focus • Genetics; extensive
    [Show full text]
  • NHMRC Administering Institutions List
    NHMRC Approved Administering Institutions This list is current as at 05 August 2020 and will be amended as required. The institutions listed below have been approved as Administering Institutions (https://nhmrc.gov.au/funding/manage-your-funding/nhmrcs-administering-institutions). Names appear as listed in NHMRC’s Research Grant Management System (RGMS). Administering Institutions are required to sign an NHMRC Funding Agreement prior to receiving any funds (https://nhmrc.gov.au/funding/manage-your-funding/funding-agreement-and-deeds-agreement) For any queries relating to approved Administering Institutions, please email [email protected]. # Entity name Australian Business Number (ABN) 1 Aboriginal Health and Medical Research Council of NSW 66085654397 2 ANZAC Research Institute 48066780055 3 Australia New Zealand Gynaecological Oncology Group 69138649028 4 Australian Catholic University Limited 15050192660 5 Australian Centre for Heart Health 87267901425 6 Australian Institute of Aboriginal and Torres Strait Islander Studies 62020533641 7 Australian National University 52234063906 8 Baker Heart and Diabetes Institute 98131762948 9 Bond University Limited 88010694121 10 Burnet Institute 49007349984 11 Cancer Council NSW 51116463846 12 Cancer Council Queensland 48321126727 13 Cancer Council Victoria 61426486715 14 Centenary Institute of Cancer Medicine and Cell Biology 22654201090 15 Central Adelaide Local Health Network Incorporated 96269526412 16 Central Australian Aboriginal Congress Aboriginal Corporation 76210591710
    [Show full text]
  • Enhancing the Commercialisation Outcomes of Health & Medical
    a Enhancing the commercialisation outcomes of health & medical research Supplementary submission to the Strategic Review of Health & Medical Research by the Association of Australian Medical Research Institutes (AAMRI) JULY / 2012 AAMRI / Supplementary submission to the McKeon Review COVER IMAGE: ©iStockphoto.com/askinkamberoglu AAMRI / Supplementary submission to the McKeon Review i Foreword The following submission is in response to a request from the McKeon Review Panel for ideas on how to increase the levels of commercially sponsored translation of Australian health and medical research. Partnership of researchers with commercial interests, including investors, venture capitalists and fund managers, as well as drug and device developers, is essential if patients are to benefit from the outcomes of health and medical research. In constructing this submission, AAMRI has therefore sought input from across the entire commercialisation ‘pipeline’. A round table discussion was held at the Baker IDI Heart and Diabetes Institute on Thursday 14 June 2012 to explore these issues. While this submission represents AAMRI’s interpretation of those discussions, all efforts have been made to represent and integrate the ideas and views of meeting participants. Round table participants > Anna-Maria Arabia, CEO, Science & Technology Australia > Dr Julian Clark, Head, Business Development, Walter & Eliza Hall Institute of Medical Research > Dr Nicole den Elzen, Executive Officer, Association of Australian Medical Research Institutes > Dr Leigh Farrell,
    [Show full text]
  • Annual Report | 2014
    Community A society that is well informed and values the benefits of health and medical research Investment Greater investment in health and medical research from all sources Prosperity Ensure Australia captures the benefits of health and medical research Position Promote Australia’s global position in health and medical research Mission To make health and medical research a higher priority for the nation Published November 2014 2 Board of Directors Research Australia’s Board reflects a balanced and effective governance structure. The membership contains technical expertise drawn from medical industry associations, medical research institutes, universities and philanthropic foundations, and companies. This technical expertise is complemented by members who bring professional expertise from business, finance, law, consumer advocacy, public policy and philanthropy. Chair Professor Janet Hiller Dean, School of Health Sciences, Professor Christine Bennett AO Swinburne University of Technology Dean of the School of Medicine, Sydney, Notre Dame University Mr Geoff Joyce Executive Director, Macquarie Capital Deputy Chair Mr Peter Wills AC Dr Anna Lavelle Respected research advocate CEO, AusBiotech Professor John McGrath Queensland Centre for Mental Health Ms Elizabeth Foley Research & Professor, Queensland Brain Managing Director, Institute, University of Queensland Research Australia Ltd Professor Alexandra McManus Dr Alison Butt Director, Centre of Excellence for Science Director, Research Investment, National Seafood & Health, Curtin University
    [Show full text]
  • Download a Pdf Version of the 2017 Convention Program
    2017 ANNUAL CONVENTION 6&7 December Hotel Realm 18 National Circuit, Barton, ACT AAMRI MEMBERS EVENT CONTACTS Peter Thomas, 0411 600 992, [email protected] Kathryn Naumenko, 0402 117 529, [email protected] Cath Latham, 0413 865 459, [email protected] 2 CONVENTION PROGRAM WED 6 DEC 9.00am REGISTRATION OPENS 9.30am-12.30pm MRI BUSINESS MANAGERS’ MEETING Pages 7-14 National Ballroom 2, Hotel Realm Canberra 12.30pm-1.30pm LUNCH National Ballroom 1, Hotel Realm Canberra 1.30pm-5.00pm AAMRI STRATEGY MEETING Pages 15-22 National Ballroom 2, Hotel Realm Canberra 5.30pm-6.30pm MRI BOARD MEMBER PRE-DINNER DRINKS High Courtyard South, Hotel Realm Canberra 6.30pm COURTESY BUSES FROM HOTEL REALM TO PARLIAMENT HOUSE Depart from the rear of Hotel Realm, in Burbury Close 7.00pm 2017 AAMRI ANNUAL DINNER Great Hall, Parliament House Guest speaker: The Hon Greg Hunt MP, Minister for Health, Minister for Sport 10.15PM Courtesy bus from Parliament House to Hotel Realm Canberra THURS 7 DEC 7.30am-8.30am AAMRI PRESIDENT’S BREAKFAST National Ballroom 2, Hotel Realm Canberra Guest speaker: The Hon Bill Shorten MP, Leader of the Opposition 8.45am-11.00am AAMRI AGM (REGISTRATION FROM 8.30AM) Pages 23-27 National Ballroom 2, Hotel Realm Canberra 3 PARTICIPANTS Mr Peter Allen Board Chair Wesley Medical Research Ms Gina Anderson Board Member The George Institute for Global Health Mr Richard Balderstone Board Olivia Newton-John Cancer Research Institute Dr Johanna Barclay Research Development Manager Mater Medical Research Institute Mr
    [Show full text]